ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.610,41
-2,40%
S&P 500
5.998,74
-0,38%
US Dollar vs BRL
6,0173
0,03%
Bitcoin
96.783,03
1,18%
Brent Oil
72,815
0,19%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Belite Bio Inc (BLTE)

  7. Belite Bio Inc (BLTE) Notícias

BLTE

Belite Bio (BLTE)

Belite Bio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BLTE
DataHoraFonteTítuloCódigoCompanhia
27/11/202405:00GlobeNewswire Inc.Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007NASDAQ:BLTEBelite Bio Inc
20/11/202420:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
12/11/202403:00GlobeNewswire Inc.Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:BLTEBelite Bio Inc
05/11/202410:00GlobeNewswire Inc.Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
04/11/202408:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLTEBelite Bio Inc
03/11/202418:00GlobeNewswire Inc.Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross ProceedsNASDAQ:BLTEBelite Bio Inc
14/10/202409:00GlobeNewswire Inc.Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual MeetingNASDAQ:BLTEBelite Bio Inc
08/10/202418:48Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:BLTEBelite Bio Inc
08/10/202409:00GlobeNewswire Inc.Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual SummitNASDAQ:BLTEBelite Bio Inc
01/10/202407:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BLTEBelite Bio Inc
26/09/202409:51GlobeNewswire Inc.Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online ViewingNASDAQ:BLTEBelite Bio Inc
17/09/202412:22GlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024NASDAQ:BLTEBelite Bio Inc
10/09/202409:00GlobeNewswire Inc.Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt DiseaseNASDAQ:BLTEBelite Bio Inc
03/09/202409:00GlobeNewswire Inc.Belite Bio to Participate in Three Upcoming Investor ConferencesNASDAQ:BLTEBelite Bio Inc
01/09/202409:00GlobeNewswire Inc.Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical OfficerNASDAQ:BLTEBelite Bio Inc
09/08/202417:30GlobeNewswire Inc.Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:BLTEBelite Bio Inc
08/08/202409:00GlobeNewswire Inc.Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:BLTEBelite Bio Inc
05/08/202420:10GlobeNewswire Inc.Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
08/07/202409:00GlobeNewswire Inc.Belite Bio to Present at the JonesHealthcare Seaside SummitNASDAQ:BLTEBelite Bio Inc
12/06/202403:55GlobeNewswire Inc.Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in JapanNASDAQ:BLTEBelite Bio Inc
14/05/202409:00GlobeNewswire Inc.Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor ConferenceNASDAQ:BLTEBelite Bio Inc
13/05/202422:50GlobeNewswire Inc.Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:BLTEBelite Bio Inc
13/05/202409:00GlobeNewswire Inc.Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:BLTEBelite Bio Inc
08/05/202409:00GlobeNewswire Inc.Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
06/05/202409:15GlobeNewswire Inc.Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On TinlarebantNASDAQ:BLTEBelite Bio Inc
06/05/202409:00GlobeNewswire Inc.Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual MeetingNASDAQ:BLTEBelite Bio Inc
01/05/202417:15GlobeNewswire Inc.Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:BLTEBelite Bio Inc
25/04/202420:15GlobeNewswire Inc.Belite Bio Announces $25 Million Registered Direct OfferingNASDAQ:BLTEBelite Bio Inc
22/03/202409:00GlobeNewswire Inc.Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanNASDAQ:BLTEBelite Bio Inc
11/03/202423:28GlobeNewswire Inc.Belite Bio Announces Availability of Annual Report on Form 20-F Through Company WebsiteNASDAQ:BLTEBelite Bio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BLTE

Seu Histórico Recente

BOV
RNEW4
RENOVA PN
BOV
HBOR3
HELBOR ON
BOV
IBOV
Índice Bovespa
BOV
GFSA3
GAFISA ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
PRIO3
PETRORIO ON
BOV
ATOM3
ATOMPAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 60%* para TRADER BRASIL

1 ano 40%, 2 anos 50% e *3 anos 60%

*Ao longo de 3 anos $ 881.64 apenas $ 352.65